[Treatment of advanced cancer of the breast with FEC polychemotherapy using epirubicin at 75 mg/m2 dose (FEC 75)]

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.

Journal of hematology & oncology·2022

Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Sarcoma·2007

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

Anti-cancer drugs·2003

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.

Journal of mass spectrometry : JMS·2002

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.

Cancer chemotherapy and pharmacology·2002

Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.

Drug development and industrial pharmacy·2001

[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].

Bulletin du cancer·2026

[Impact of a geriatric oncology tumor-board on medical decision-making in patients aged 70 and over with cancer].

Bulletin du cancer·2026

[Effects of phytoestrogens on prognosis and hormonal markers of breast cancer: A systematic review of randomized controlled trials].

Bulletin du cancer·2026

[Indications for chimerism analysis on sorted cell populations after allogeneic hematopoietic stem cell transplantation (SFGM-TC)].

Bulletin du cancer·2026

[Telemonitoring in Oncology: A French overview between 2022 and 2025].

Bulletin du cancer·2026

[Antibiotic use following pediatric hematopoietic stem cell transplantation (SFGM-TC)].

Bulletin du cancer·2026

TREM2+ macrophages mediate anticancer therapy-induced immune evasion in lung adenocarcinoma via the CCL5/CCL22-Treg axis.

Frontiers in immunology·2026

Complications of clozapine cessation in the context of chemotherapy-related neutropenia-a case report.

Frontiers in oncology·2026

PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data.

Frontiers in immunology·2026

Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study.

Frontiers in oncology·2026

Co-delivery of siPD-L1 and Tat-HSPB1 by G5PBA Enhances the Efficacy of Antitumor Therapy in Clear Cell Renal Cell Carcinoma.

Bioconjugate chemistry·2026

A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.

Bioconjugate chemistry·2026

Related Experiment Videos

[Treatment of advanced cancer of the breast with FEC polychemotherapy using epirubicin at 75 mg/m2 dose (FEC 75)]

Related Concept Videos

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.

Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.

Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.

[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].

[Impact of a geriatric oncology tumor-board on medical decision-making in patients aged 70 and over with cancer].

[Effects of phytoestrogens on prognosis and hormonal markers of breast cancer: A systematic review of randomized controlled trials].

[Indications for chimerism analysis on sorted cell populations after allogeneic hematopoietic stem cell transplantation (SFGM-TC)].

[Telemonitoring in Oncology: A French overview between 2022 and 2025].

[Antibiotic use following pediatric hematopoietic stem cell transplantation (SFGM-TC)].

TREM2+ macrophages mediate anticancer therapy-induced immune evasion in lung adenocarcinoma via the CCL5/CCL22-Treg axis.

Complications of clozapine cessation in the context of chemotherapy-related neutropenia-a case report.

PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data.

Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study.

Co-delivery of siPD-L1 and Tat-HSPB1 by G5PBA Enhances the Efficacy of Antitumor Therapy in Clear Cell Renal Cell Carcinoma.

A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.

Related Experiment Videos

[Treatment of advanced cancer of the breast with FEC polychemotherapy using epirubicin at 75 mg/m2 dose (FEC 75)]

Related Concept Videos

Related Articles